XBI vs IBB — what's the difference?

The core difference is weighting methodology. XBI is equal-weighted: every one of its ~150 holdings gets roughly the same portfolio weight, regardless of company size. A small biotech with a pending FDA decision has the same impact on performance as a large company with stable revenues. IBB is cap-weighted and dominated by mega-cap names like AbbVie, Amgen, and Gilead — which are really large pharmaceutical companies that happen to have some biotech exposure. If your thesis is pure biotech innovation and asymmetric upside from smaller companies, XBI is the right vehicle. If you want defensive healthcare exposure with dividend-paying pharma giants, IBB (or XLV) is more appropriate.

Is XBI a good investment?

XBI is a good investment if your thesis is that biotech innovation will drive outsized returns and you can tolerate significant volatility. The equal-weighting approach means you get real exposure to the companies most likely to produce binary outcomes — FDA approvals, breakthrough data reads, acquisition targets. But it also means those same events can devastate the fund in a single day. XBI is not a good investment if you want steady income, low volatility, or defensive positioning. It belongs in Dare precisely because it's volatile and asymmetric: big upside potential paired with real downside risk.

Why is XBI so volatile?

XBI's volatility comes from two sources. First, biotech companies are inherently volatile — their stock prices swing on clinical trial results, FDA decisions, and M&A speculation. Second, and more importantly for XBI specifically, the equal-weighting approach means small-cap biotechs (which can move 50-100% on a single day) have the same portfolio weight as large companies. When multiple holdings report bad data or face FDA rejections simultaneously — which happened dramatically in 2021-2022 — XBI can drop 60-70% from peak to trough. That drawdown is not an anomaly; it's baked into the fund's structure.

How does equal weighting affect XBI?

Equal weighting means every holding in XBI has roughly the same portfolio weight — approximately 0.67% for ~150 holdings. This is fundamentally different from cap-weighted funds like IBB where the largest companies can represent 10-15% of the fund individually. For XBI, a small biotech company with one pending FDA decision has the same impact on performance as a large company generating billions in annual revenue. That's what creates the asymmetric upside: if several small holdings get FDA approvals or acquisition offers, they can each move 50-100% and meaningfully lift the entire fund. But it also means bad news from smaller companies hits just as hard.

Does XBI pay dividends?

Yes, but very little. XBI pays quarterly distributions with a 30-day SEC yield typically in the 0.1-0.3% range. Most of its ~150 holdings are growth-stage biotech companies that reinvest everything into R&D rather than paying dividends. The tiny yield is essentially noise compared to the fund's price volatility — don't buy XBI for income. Buy it for the asymmetric upside potential from FDA binary events and clinical trial catalysts across a diversified basket of biotech names.

What happened to XBI in 2021-2022?

XBI experienced one of the worst drawdowns among major ETFs, falling approximately 60-70% from its mid-2021 peak. The biotech sector was massively overvalued after a multi-year bull run fueled by low interest rates and pandemic-era innovation enthusiasm. When rates rose sharply in 2022, growth-oriented biotech valuations collapsed. Small-cap equal-weighted holdings were hit hardest because they're most sensitive to discount rate changes and have the least revenue cushion. This drawdown is exactly why XBI belongs in Dare — it demonstrates the real downside risk that comes with the asymmetric upside thesis.

Dare fund AMEX:XBI

XBI: SPDR S&P Biotech ETF

Biotech without the pharma dilution. Equal-weighted exposure to ~150 companies where a small biotech with a pending FDA decision has the same portfolio weight as a large company with stable revenues.

Michael Ashley — Banking and asset management, 20+ years Updated May 17, 2026

This is analysis, not personalized investment advice. Do your own homework before making decisions.